GlassScriptPhysician profile
Ruth A Whiddon
NPI 1366428005
$3,985.03
in general payments reported to CMS, 2019-2025
21 companies · $732 in 2025
The $732 reported for 2025 was more than what 93% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $611 · 2022: $721 · 2023: $1,234 · 2024: $687 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.67 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $783.27 | 2023-2025 | Veozah |
| Abbvie INC. | $504.39 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $498.45 | 2021-2025 | |
| Millicent US INC | $389.20 | 2022-2025 | Intrarosa, Femlyv, Femring |
| Exeltis, USA INC. | $300.12 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $290.62 | 2023-2024 | Myfembree |
| Pfizer INC. | $257.25 | 2021-2024 | |
| Sage Therapeutics, LLC | $149.04 | 2024-2025 | Zurzuvae |
| Organon LLC | $141.32 | 2021-2025 | Nexplanon |
| Agile Therapeutics, INC. | $120.21 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $118.35 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $115.67 | 2021-2023 | |
| Myovant Sciences INC. | $112.34 | 2021-2022 | |
| Hologic Sales and Service, LLC | $55.19 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Avion Pharmaceuticals | $47.16 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23.72 | 2022 | |
| Supernus Pharmaceuticals, INC. | $20.40 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $19.19 | 2021 | |
| Lupin INC. | $14.32 | 2021 | |
| Merck Sharp & Dohme LLC | $12.88 | 2021 | |
| Integra Lifesciences Corporation | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Whiddon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.